Expression of EZH2, a transcriptional target of MYCN, is associated with neuroblastoma outcome, and inhibition of this histone methyltransferase by genetic or pharmacologic means, leads to neuroblastoma growth inhibition43,44,52–54. This evidence concerns the gene EZH2 and neuroblastoma.